Medical Device Investment Highlights (Sep 28 – Oct 18, 2024): Innovations in Regenerative Biomaterials, Polymer Heart Valves, Radiopharmaceutical CRO, Transdermal Patches, and Ultrasound Nucleic Acid Systems

Suzhou Pujubio Biotechnology Co., Ltd. (hereinafter referred to as "Pujubio") recently announced that the company has completed a multi-million RMB Series A round of financing. This round of financing was exclusively invested by Mifang Capital, with the financing amount ranking in the top 50% of all Series A financings this year. Headquartered in Suzhou, Pujubio is an innovative enterprise focused on the research and development of biological materials for soft tissue regeneration.

Pujubio is committed to building a bioactive filling material engineering platform, aiming to launch globally leading high-end regenerative medicine material products, providing new material solutions for medical aesthetics and anti-aging across all age groups. The company's core products include multi-form inorganic materials based on nano-level calcium phosphate salts, which can achieve precise control over microsphere structure and particle size distribution, and effectively remove pyrogens and other impurities to meet the demands of different products for various forms.

The CaHA medical aesthetic injectable filler product Rejuve from Pujü Bio demonstrates key metrics such as microsphere uniformity and viscoelastic performance that are either superior to or highly consistent with the leading product Radiesse on the market. Currently, the nearly 200 cases of registration clinical trials for Rejuve have completed full enrollment and have achieved over six months of follow-up. The trial results have consistently shown the company’s product to possess strong immediate filling effects, induced regenerative capabilities, and long-term safety.

In addition, Pujubio has also developed multiple products in surgical and filling categories based on the treatment needs of beauty seekers at different stages of aging. These products have all completed preliminary R&D prototyping and are planned to be gradually pushed into clinical trial stages within the next year.

Suzhou Xinrui Medical Technology Co., Ltd. (hereinafter referred to as "Xinrui Medical") recently announced that the company has completed a multi-million RMB A+ round of financing. This round of financing was led by Huaying Investment, with the amount ranking in the top 50% of all A+ rounds of financing this year. Headquartered in Suzhou, Xinrui Medical is an innovative enterprise focusing on the research and development of polymer valves.

Xinrui Medical was established on December 27, 2021, and is dedicated to the frontier field of heart valve disease treatment. The company focuses on polymer-based heart valves as its core, developing a comprehensive solution for heart valve diseases. Xinrui Medical's polymer valve products combine the advantages of mechanical and biological valves, offering excellent fatigue resistance and superior blood compatibility, marking a significant breakthrough in the field of heart valve treatment.

The core team of the company is composed of internationally leading scientists, covering multiple fields such as neuroscience, clinical medicine, multi-physics sensing, and medical engineering. AccuBrain Medical has accumulated extensive experience in neuromodulation and physiological monitoring technology and their clinical translation, successfully building a composite product line covering animal and human EEG.

This round of financing will be used to accelerate the product development and market promotion of Xinrui Medical, in order to better serve patients with valvular heart disease. The company plans to use this fund to strengthen the R&D of AI technology, optimize health analysis algorithms, expand the service scope of the precision nutrition recommendation platform, and further extend cooperation within the healthcare field.

Beijing Quark Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Quark Pharma") recently announced that the company has successfully completed a multi-million RMB Series A round of financing. This round of financing was jointly invested by Mint Venture Capital, Guoshun Investment, and Taikun Fund, with the financing amount ranking in the top 50% of all Series A financings this year. Headquartered in Beijing, Quark Pharma is a high-tech enterprise specializing in nuclear medicine clinical CRO services.

Since its establishment in 2011, Quark Pharmaceutical has been committed to providing comprehensive clinical research services, covering areas such as bioassay, clinical research of innovative drugs, clinical research of generic drugs, data statistics, and IRC. The company has achieved remarkable success in the field of radiopharmaceuticals, including acting as a CRO responsible for the Phase III clinical study of the first new product in China for detecting bone metastases in cancer patients, which was successfully approved and launched.

Quark Medicine's expertise and clinical execution capabilities in the field of radiopharmaceuticals have demonstrated significant synergies in emerging areas such as the central nervous system (CNS) and gene and cell therapy (CGT). The company’s established clinical research service system for radiopharmaceuticals has not only improved the efficiency and quality of clinical trials but also saved customers considerable time and resources.

Quark Pharmaceutical's service network covers multiple regions in China, including Beijing, Shanghai, Guangzhou, Hangzhou, Chengdu, Wuhan, Zhengzhou, Shenyang, and more, with branch offices and representative offices established. The company’s international registration services extend to regions such as Europe, Australia, and North America. Quark Pharmaceutical continuously explores the integration of artificial intelligence with clinical research and advances the digital transformation of clinical management.

The success of this Series A round of financing will provide momentum for Quark Pharmaceuticals to further explore the field of radiopharmaceuticals and empower the company to enhance its overall multi-center clinical service capabilities.

Zhejiang Haigetang Pharmaceutical Co., Ltd. (hereinafter referred to as "Haigetang Pharmaceutical") recently announced the completion of a multi-million RMB Series A financing round. The funds from this round will mainly be used for the company's research and development innovation, production implementation, brand building, and market promotion, marking a solid and significant step in the innovative development of Haigetang Pharmaceutical in the field of transdermal drug delivery.

Haigetang Pharmaceutical is an innovative enterprise focused on the production of transdermal drug patches, with its headquarters located in Zhejiang Province, China. The company is committed to leading innovation in transdermal drug patches, disrupting traditional drug treatment models, and has become a pharmaceutical technology enterprise with international competitiveness, integrating both generic and innovative capabilities. After years of accumulation, Haigetang Pharmaceutical's R&D pipeline for transdermal drug patches covers multiple disease areas including respiratory, central nervous system, metabolic diseases, endocrine, and cardiovascular and cerebrovascular conditions. Meanwhile, the company’s independently developed, world-first health patches encompass a variety of nutritional supplements across major health fields such as sleep aid, beauty, liver protection, and anti-fatigue, forming a rich and competitive R&D pipeline.

Haige Hall Pharmaceutical's transdermal drug delivery technology aims to provide a more convenient method of administration, improve the medication experience for patients, and is expected to break the technological monopoly of Europe, America, and Japan in this field, offering high-quality treatment options to more patients worldwide. With significant advantages such as self-administration and painlessness, transdermal formulations can effectively overcome the challenges faced by traditional drug delivery methods in specific patient populations, greatly enhancing the quality of life for patients.

The injection of this round of funding will further accelerate the development of new products and market expansion for Haigetang Pharmaceutical. Currently, the company has several products in the late stages of development, which are expected to be launched successively in the coming years. As a young company, Haigetang Pharmaceutical completed its Series A financing in a short period of time, demonstrating the capital market's recognition of its R&D capabilities and innovative strength.

Shenzhen Dayuan Chenguang Technology Co., Ltd. (hereinafter referred to as "Dayuan Chenguang") recently announced that the company has completed a Pre-A round of financing worth tens of millions of RMB. This round of financing was led by Yahelon (stock code: 688575), with Yanghe Investment following suit. The funds raised will mainly be used for global market development, new product research and development, and production capacity enhancement, to support the improvement of the company's product line and the advancement of its internationalization strategy.

Dayuan Chenguang is a company focused on providing comprehensive diagnostic research and molecular biology solutions for future laboratory needs. The company’s team consists of university professors, overseas technical experts, and senior industry professionals, possessing extensive industry experience and multidisciplinary technical expertise. Dayuan Chenguang is committed to offering products and services of international quality for biopharmaceutical research, translational medical research, and basic scientific research through fundamental scientific studies.

The first focused ultrasound sample processing system in China, launched by the company, has achieved a significant market share and is widely used for the extraction and preparation of single-cell proteomics samples. In addition, Dawayuan Biotech has also introduced uniform magnetic field separation products, ultra-fast macromolecule separation technology, and cryo-electron microscopy structural analysis services, providing comprehensive solutions for global life science research.

Currently, the products of Dayuan Chenguang have been sold to overseas regions such as Europe, Japan, and the Americas. With the injection of this round of financing, Dayuan Chenguang will further increase its R&D efforts, expand its product pipeline, create new growth engines, and explore broader global markets.